European Regulator Approve New AstraZeneca Ovarian Cancer Drug

December 18, 2014 11:29 AM

12 0

While the drug has hit some snags in the United States, AstraZeneca’s new ovarian cancer drug—the first of its kind—has received approval in the European Union. The new drug, olaparib, will reach the market under the brand name Lynparza and will target a very specific subset of ovarian cancer (high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer).

AstraZeneca chief medical officer Briggs Morrison said “Today’s approval marks a significant milestone in the development of the next generation of targeted medicines.” This medicine specifically targets the action of proteins called PARP which help repair DNA.

Read more

To category page